372 related articles for article (PubMed ID: 32999024)
61. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
Dubrovskaya V; Guenaga J; de Val N; Wilson R; Feng Y; Movsesyan A; Karlsson Hedestam GB; Ward AB; Wyatt RT
PLoS Pathog; 2017 Sep; 13(9):e1006614. PubMed ID: 28902916
[TBL] [Abstract][Full Text] [Related]
62. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.
Sliepen K; Han BW; Bontjer I; Mooij P; Garces F; Behrens AJ; Rantalainen K; Kumar S; Sarkar A; Brouwer PJM; Hua Y; Tolazzi M; Schermer E; Torres JL; Ozorowski G; van der Woude P; de la Peña AT; van Breemen MJ; Camacho-Sánchez JM; Burger JA; Medina-Ramírez M; González N; Alcami J; LaBranche C; Scarlatti G; van Gils MJ; Crispin M; Montefiori DC; Ward AB; Koopman G; Moore JP; Shattock RJ; Bogers WM; Wilson IA; Sanders RW
Nat Commun; 2019 May; 10(1):2355. PubMed ID: 31142746
[TBL] [Abstract][Full Text] [Related]
63. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
[TBL] [Abstract][Full Text] [Related]
64. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.
Capucci S; Wee EG; Schiffner T; LaBranche CC; Borthwick N; Cupo A; Dodd J; Dean H; Sattentau Q; Montefiori D; Klasse PJ; Sanders RW; Moore JP; Hanke T
PLoS One; 2017; 12(8):e0181886. PubMed ID: 28792942
[TBL] [Abstract][Full Text] [Related]
65. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
66. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
[TBL] [Abstract][Full Text] [Related]
67. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.
Antanasijevic A; Sewall LM; Cottrell CA; Carnathan DG; Jimenez LE; Ngo JT; Silverman JB; Groschel B; Georgeson E; Bhiman J; Bastidas R; LaBranche C; Allen JD; Copps J; Perrett HR; Rantalainen K; Cannac F; Yang YR; de la Peña AT; Rocha RF; Berndsen ZT; Baker D; King NP; Sanders RW; Moore JP; Crotty S; Crispin M; Montefiori DC; Burton DR; Schief WR; Silvestri G; Ward AB
Nat Commun; 2021 Aug; 12(1):4817. PubMed ID: 34376662
[TBL] [Abstract][Full Text] [Related]
68. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.
Carbonetti S; Oliver BG; Glenn J; Stamatatos L; Sather DN
PLoS One; 2014; 9(1):e86905. PubMed ID: 24466285
[TBL] [Abstract][Full Text] [Related]
69. VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA.
Jia M; Liberatore RA; Guo Y; Chan KW; Pan R; Lu H; Waltari E; Mittler E; Chandran K; Finzi A; Kaufmann DE; Seaman MS; Ho DD; Shapiro L; Sheng Z; Kong XP; Bieniasz PD; Wu X
Cell Host Microbe; 2020 Jun; 27(6):963-975.e5. PubMed ID: 32315598
[TBL] [Abstract][Full Text] [Related]
70. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review.
Derking R; Sanders RW
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25797. PubMed ID: 34806305
[TBL] [Abstract][Full Text] [Related]
71. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
LaBranche CC; Henderson R; Hsu A; Behrens S; Chen X; Zhou T; Wiehe K; Saunders KO; Alam SM; Bonsignori M; Borgnia MJ; Sattentau QJ; Eaton A; Greene K; Gao H; Liao HX; Williams WB; Peacock J; Tang H; Perez LG; Edwards RJ; Kepler TB; Korber BT; Kwong PD; Mascola JR; Acharya P; Haynes BF; Montefiori DC
PLoS Pathog; 2019 Sep; 15(9):e1008026. PubMed ID: 31527908
[TBL] [Abstract][Full Text] [Related]
72. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.
de Taeye SW; Moore JP; Sanders RW
Trends Immunol; 2016 Mar; 37(3):221-232. PubMed ID: 26869204
[TBL] [Abstract][Full Text] [Related]
73. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.
Dey AK; Cupo A; Ozorowski G; Sharma VK; Behrens AJ; Go EP; Ketas TJ; Yasmeen A; Klasse PJ; Sayeed E; Desaire H; Crispin M; Wilson IA; Sanders RW; Hassell T; Ward AB; Moore JP
Biotechnol Bioeng; 2018 Apr; 115(4):885-899. PubMed ID: 29150937
[TBL] [Abstract][Full Text] [Related]
74. Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVC
Tumba NL; Owen GR; Killick MA; Papathanasopoulos MA
Vaccine X; 2022 Dec; 12():100222. PubMed ID: 36262212
[No Abstract] [Full Text] [Related]
75. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
76. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
Sun Z; Li J; Hu X; Shao Y; Zhang MY
Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
[TBL] [Abstract][Full Text] [Related]
77. Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.
Behrens AJ; Kumar A; Medina-Ramirez M; Cupo A; Marshall K; Cruz Portillo VM; Harvey DJ; Ozorowski G; Zitzmann N; Wilson IA; Ward AB; Struwe WB; Moore JP; Sanders RW; Crispin M
J Proteome Res; 2018 Mar; 17(3):987-999. PubMed ID: 29420040
[TBL] [Abstract][Full Text] [Related]
78. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
Antanasijevic A; Ueda G; Brouwer PJM; Copps J; Huang D; Allen JD; Cottrell CA; Yasmeen A; Sewall LM; Bontjer I; Ketas TJ; Turner HL; Berndsen ZT; Montefiori DC; Klasse PJ; Crispin M; Nemazee D; Moore JP; Sanders RW; King NP; Baker D; Ward AB
PLoS Pathog; 2020 Aug; 16(8):e1008665. PubMed ID: 32780770
[TBL] [Abstract][Full Text] [Related]
79. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
[TBL] [Abstract][Full Text] [Related]
80. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
